scholarly journals Herpes Zoster in a 2-Year-Old Child After a Single Dose of Varicella Vaccine

2021 ◽  
Vol 5 (2) ◽  
pp. 166-169
Author(s):  
Hope Barone ◽  
Mary Veremis ◽  
Stuart Gildenberg

In this report, we describe a rare case of an immunocompetent 2-year-old child who developed herpes zoster (HZ) in the same dermatomal distribution as the vaccination site received several months prior. Although most cases of HZ caused by the vaccine-strain virus follow a mild disease course, affected patients are contagious to household members and may nevertheless develop severe complications such as herpes ophthalmicus and meningoencephalitis. Consideration of this entity and associated complications is critical for dermatologists when evaluating similar appearing eruptions.

Author(s):  
Rana Swed-Tobia ◽  
Imad Kassis ◽  
Suhair Hanna ◽  
Moran Szwarcwort-Cohen ◽  
Sara Dovrat ◽  
...  

PEDIATRICS ◽  
2007 ◽  
Vol 120 (5) ◽  
pp. e1345-e1349 ◽  
Author(s):  
P. Jean-Philippe ◽  
A. Freedman ◽  
M. W. Chang ◽  
S. P. Steinberg ◽  
A. A. Gershon ◽  
...  

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S975-S976
Author(s):  
Sheila Weinmann ◽  
Stephanie Irving ◽  
Padma Koppolu ◽  
Allison Naleway ◽  
Edward Belongia ◽  
...  

Abstract Background Varicella (VAR) and measles-mumps-rubella (MMR) vaccines are recommended for children at ages 12–15 months and 4–6 years. These are administered as separate MMR and VAR vaccines (MMR+VAR) or as combined measles-mumps-rubella-varicella (MMRV) vaccine. Herpes zoster (HZ), caused by wild-type or vaccine-strain varicella-zoster virus, can occur in children after varicella vaccination. It is unknown whether HZ incidence after varicella vaccination varies by vaccine formulation or simultaneous receipt of MMR. Methods Using data from six integrated health systems, we examined HZ incidence among children who turned 12 months old during 2003–2008 and received varicella and MMR vaccines according to routine recommendations. All HZ cases ≥ 21 days after first varicella vaccination were identified using ICD-9 codes from inpatient, outpatient, emergency room encounters, and claims data, through 2014. HZ incidence was examined by vaccine formulation (MMR+VAR, MMRV, or VAR without same-day MMR) and doses received and compared using incidence rate ratios (IRR). Results Among 199,797 children, we identified 601 HZ cases. Crude HZ incidence after first-dose MMR+VAR (18.6 [95% CI 11.1–29.2] cases/100,000 person-years) was similar to the rate after first-dose MMRV (17.9 [95% CI 10.6–28.3] cases/100,000 person-years), but approximately double the rate among those with first-dose VAR without same-day MMR (7.5 [95% CI 3.1–15.0] cases/100,000 person-years); see Table 1. The IRR for HZ after first-dose MMR+VAR or MMRV, compared with VAR, was 2.5 (95% CI 1.4–4.4; P = 0.002). When examining any first or second dose formulation, crude HZ incidence was lower after the second varicella vaccine dose (13.9 cases/100,000 person-years), than in the period before the second dose (i.e., between first and second doses or after the first dose in children with only one dose; 21.8 cases/100,000 person-years, P < 0.0001). HZ incidence was also lower after two varicella vaccine doses in each of the three first-dose formulation groups. Conclusion HZ incidence among children varied by first-dose varicella vaccine formulation and number of varicella vaccine doses. Regardless of the first-dose varicella vaccine formulation, children who received two vaccine doses had lower HZ incidence after the second dose. Disclosures All authors: No reported disclosures.


2001 ◽  
Vol 5 (5) ◽  
pp. 409-416 ◽  
Author(s):  
Melody Vander Straten ◽  
Daniel Carrasco ◽  
Patricia Lee ◽  
Stephen K. Tyring

Background: Persons 50 years of age and older are not only at increased risk of developing herpes zoster, they are also more likely to suffer the long-term morbidity of postherpetic neuralgia (PHN). PHN is pain persisting after the rash of herpes zoster has healed. PHN affects at least 40% of all herpes zoster patients over age 50 and over 75% of herpes zoster patients over age 75; PHN is the single most common neurologic condition in elderly patients. Objective: The objective of this review is to evaluate interventions that may reduce or even eliminate PHN. No single therapy has been consistently effective for PHN. The most effective approach appears to be with the use of antiviral therapy early in the course of herpes zoster. The goals of ongoing studies in herpes zoster are to develop interventions that will further reduce the symptoms of PHN and/or to eliminate PHN by prophylaxis using the varicella vaccine. Conclusions: Reduction of PHN can best be achieved with the use of antiviral medication early in the course of herpes zoster; other classes of drugs are minimally effective in treating established PHN. Widespread use of the varicella vaccine may lead to secondary reductions in PHN in the distant future.


2002 ◽  
Vol 6 (7) ◽  
Author(s):  
N Noah

Chickenpox is now one of the last of the infectious diseases of childhood that remain mostly uncontrolled. An effective vaccine has been available for many years but has not been used for routine immunisation in many countries. This is because the effect of giving the vaccine in early life on the subsequent development of herpes zoster is not known; high immunisation rates are important to ensure that the age distribution does not shift towards older age groups in whom the disease is more serious; and the disease is generally considered innocuous, especially in childhood when about 95% of infections occur.


Vaccine ◽  
2018 ◽  
Vol 36 (6) ◽  
pp. 833-840 ◽  
Author(s):  
James M. McCarty ◽  
Michael D. Lock ◽  
Kristin M. Hunt ◽  
Jakub K. Simon ◽  
Marc Gurwith

PEDIATRICS ◽  
1986 ◽  
Vol 77 (1) ◽  
pp. 53-56
Author(s):  
Philip A. Brunell ◽  
Jean Taylor-Wiedeman ◽  
Clementina F. Geiser ◽  
Lisa Frierson ◽  
Eva Lydick

A study was undertaken to determine whether children immunized with live varicella vaccine are at greater risk of acquiring herpes zoster than children who have had varicella. Children with acute lymphocytic leukemia who had had varicella were compared with those who received live varicella vaccine. During the period of observation, 15 of 73 children who had varicella acquired herpes zoster and none of the 34 children who had been vaccinated. If the time of observation was adjusted for and the vaccinees who failed to have a sustained antibody response or who acquired chickenpox were removed, the risk of herpes zoster was still less in vaccinees (P = .0075). Because herpes zoster is common in children with acute lymphocytic leukemia, differences in the two groups could be discerned more readily than if normal children were compared. There is no reason to suspect that recipients of live varicella vaccine would be more likely to acquire herpes zoster than children who get varicella.


Sign in / Sign up

Export Citation Format

Share Document